Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Depreciation and Depletion (2016 - 2025)

Avanos Medical (AVNS) has disclosed Depreciation and Depletion for 13 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion rose 14.89% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.7 million through Dec 2025, down 2.96% year-over-year, with the annual reading at $19.7 million for FY2025, 2.96% down from the prior year.
  • Depreciation and Depletion hit $5.4 million in Q4 2025 for Avanos Medical, up from $5.0 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $5.5 million in Q1 2021 to a low of $700000.0 in Q4 2021.
  • Historically, Depreciation and Depletion has averaged $4.7 million across 5 years, with a median of $5.0 million in 2023.
  • Biggest five-year swings in Depreciation and Depletion: plummeted 88.33% in 2021 and later surged 500.0% in 2022.
  • Year by year, Depreciation and Depletion stood at $700000.0 in 2021, then soared by 500.0% to $4.2 million in 2022, then increased by 19.05% to $5.0 million in 2023, then decreased by 6.0% to $4.7 million in 2024, then rose by 14.89% to $5.4 million in 2025.
  • Business Quant data shows Depreciation and Depletion for AVNS at $5.4 million in Q4 2025, $5.0 million in Q3 2025, and $4.8 million in Q2 2025.